RdC regimen
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
RdC regimen refers to a regimen consisting of Lenalidomide (Revlimid), dexamethasone, Cyclophosphamide used to treat AL amyloidosis.[1]
Regimen
RRevlimid (Lenalidomide)
ddexamethasone
CCyclophosphamide
Indications
References
- ↑ 1.0 1.1 Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Pamboukas C, Boletis I; et al. (2012). “A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis”. Blood. 119 (23): 5384–90. doi:10.1182/blood-2011-12-396903. PMID 22517904.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH